0001193125-13-055243.txt : 20130213
0001193125-13-055243.hdr.sgml : 20130213
20130213155825
ACCESSION NUMBER: 0001193125-13-055243
CONFORMED SUBMISSION TYPE: 13F-HR
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20121231
FILED AS OF DATE: 20130213
DATE AS OF CHANGE: 20130213
EFFECTIVENESS DATE: 20130213
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: BB BIOTECH AG
CENTRAL INDEX KEY: 0000924223
STATE OF INCORPORATION: V8
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 13F-HR
SEC ACT: 1934 Act
SEC FILE NUMBER: 028-06964
FILM NUMBER: 13602980
BUSINESS ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
BUSINESS PHONE: 411724 59 59
MAIL ADDRESS:
STREET 1: VODERGASSE 3
STREET 2: SWITZERLAND
CITY: SCHAFFHAUSEN
STATE: V8
ZIP: CH-8300
13F-HR
1
d485964d13fhr.txt
FORM 13F-HR
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 13F
Form 13F COVER PAGE
Report for Calendar Year or Quarter Ended: December 31, 2012
Check here if Amendment [_]; Amendment Number:
This Amendment (Check only one.): [_] is a restatement.
[_] adds new holdings
entries.
Institutional Investment Manager Filing this Report:
Name: BB Biotech AG
Address: Vordergasse 3
Schaffhausen Switzerland CH-8200
Form 13F File Number: 28-6964
The institutional investment manager filing this report and the person by whom
it is signed hereby represent that the person signing the report is authorized
to submit it, that all information contained herein is true, correct and
complete, and that it is understood that all required items, statements,
schedules, lists, and tables are considered integral parts of this form.
Person Signing this Report on Behalf of Reporting Manager:
Name: Pascal Schmucki
Title: SIGNING AUTHORITY
Phone: 41 (44) 267 67 00
Signature, Place, and Date of Signing: /s/ Pascal Schmucki
---------------------------------------------
Schaffhausen, Switzerland, February 12, 2013
Report Type (Check only one.):
[X] 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager
are reported in this report.)
[_] 13F NOTICE. (Check here if no holdings reported are in this report, and all
holdings are reported by other reporting manager(s).)
[_] 13F COMBINATION REPORT. (Check here if a portion of the holdings for this
reporting manager are reported in this report and a portion are reported by
other reporting manager(s).)
1
Form 13F SUMMARY PAGE
Report Summary:
Number of Other Included Managers: 3
Form 13F Information Table Entry Total: 19
Form 13F Information Table Value Total: $ 1,029,291
--------------
(thousands)
List of Other Included Managers:
Provide a numbered list of the name(s) and Form 13F file number(s) of all
institutional investment managers with respect to which this report is filed,
other than the manager filing this report.
No. Form 13F File Number Name
1 28-11193 Biotech Focus N.V.
2 28-11191 Biotech Invest N.V.
3 28-11189 Biotech Target N.V.
2
BB BIOTECH AG
FORM 13F INFORMATION TABLE
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
--------------------- --------- ---------- ---------- ---------------------- ----------- --------- -----------------------
TITLE OF VALUE SHS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE
--------------------- --------- ---------- ---------- --------- ----- ---- ----------- --------- ---------- ------ -----
Achillion
Pharmaceuticals
Inc COM 00448Q201 13,452 1,679,340 SH DEFINED 3 1,679,340 NONE NONE
Alexion
Pharmaceuticals
Inc COM 015351109 42,183 450,000 SH DEFINED 2 450,000 NONE NONE
Ariad
Pharmaceuticals
Inc COM 04033A100 49,620 2,587,075 SH DEFINED 3 2,587,075 NONE NONE
Biomarin
Pharmaceutical
Inc COM 09061G101 36,102 733,787 SH DEFINED 2 733,787 NONE NONE
Celgene Corp COM 151020104 209,529 2,670,186 SH DEFINED 2 2,670,186 NONE NONE
Dendreon Corp COM 24823Q107 8,065 1,524,500 SH DEFINED 2 1,524,500 NONE NONE
Endocyte Inc COM 29269A102 18,529 2,063,352 SH DEFINED 3 2,063,352 NONE NONE
Gilead Sciences Inc COM 375558103 147,635 2,010,000 SH DEFINED 1 2,010,000 NONE NONE
Halozyme
Therapeutics Inc COM 40637H109 37,418 5,576,519 SH DEFINED 3 5,576,519 NONE NONE
Idenix
Pharmaceuticals
Inc COM 45166R204 6,063 1,250,000 SH DEFINED 3 1,250,000 NONE NONE
Immunogen Inc COM 45253H101 45,281 3,551,432 SH DEFINED 3 3,551,432 NONE NONE
Incyte Corp COM 45337C102 85,103 5,123,617 SH DEFINED 3 5,123,617 NONE NONE
Isis
Pharmaceuticals
Inc COM 464330109 83,970 8,043,140 SH DEFINED 3 8,043,140 NONE NONE
Medivation, Inc COM 58501N101 49,196 961,606 SH DEFINED 3 961,606 NONE NONE
Onyx
Pharmaceuticals
Inc COM 683399109 41,277 546,500 SH DEFINED 2 546,500 NONE NONE
Optimer
Pharmaceuticals
Inc COM 68401H104 13,093 1,446,700 SH DEFINED 3 1,446,700 NONE NONE
The Medicines Co COM 584688105 37,835 1,578,417 SH DEFINED 2 1,578,417 NONE NONE
Theravance Inc COM 88338T104 19,755 888,244 SH DEFINED 3 888,244 NONE NONE
Vertex
Pharmaceuticals Inc COM 92532F100 85,186 2,033,085 SH DEFINED 3 2,033,085 NONE NONE
3